ANAB
AnaptysBio, Inc.
Price Chart
Latest Quote
$50.37
-1.30 (-2.52%)
Current Price
| Previous Close | $51.67 |
| Open | $50.58 |
| Day High | $52.28 |
| Day Low | $50.36 |
| Volume | 511,962 |
Stock Information
| Shares Outstanding | 29.10M |
| Total Debt | $277.36M |
| Cash Equivalents | $286.46M |
| Revenue | $232.39M |
| Net Income | $-26.79M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.47B |
| EPS (TTM) | $-1.02 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.46B |
| Sales | $232.39M |
| Income | $-26.79M |
| Book/sh | $0.44 |
| Cash/sh | $9.84 |
| Employees | 104 |
Financial Ratios
| Quick Ratio | 7.49 |
| Current Ratio | 7.58 |
| Debt/Eq | 2175.84 |
Returns & Margins
| ROA | 6.78% |
| ROE | -114.55% |
| Gross Margin | 44.58% |
| Operating Margin | -135.53% |
| Profit Margin | -11.53% |
Ownership
| Insider Ownership | 5.74% |
| Institutional Ownership | 103.60% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 8.64 |
| P/S | 6.31 |
| P/B | 114.74 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $84.45 |
Technical Indicators
| SMA20 | $58.77 |
| SMA50 | $54.42 |
| SMA200 | $34.17 |
| RSI | 12.37 |
| ATR | 2.7604 |
| Shares Float | 19.55M |
| Short Float | 23.77% |
| Short Ratio | 6.61 |
| Volatility | 0.41 |
| Rel Volume | 1.06 |
Performance History
| Week | -9.52% |
| Month | -25.22% |
| Quarter | +36.36% |
| 6 Months | +72.66% |
| YTD | +68.09% |
| Year | +255.22% |
| 3 Years | +295.58% |
| 5 Years | +216.53% |
| 10 Years | +344.44% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $50.37 | 612,000 |
| 2026-06-04 | $51.67 | 324,000 |
| 2026-06-03 | $51.24 | 933,700 |
| 2026-06-02 | $51.26 | 819,800 |
| 2026-06-01 | $53.14 | 725,100 |
| 2026-05-29 | $55.67 | 502,100 |
| 2026-05-28 | $57.02 | 619,800 |
| 2026-05-27 | $57.69 | 666,900 |
| 2026-05-26 | $57.77 | 482,200 |
| 2026-05-22 | $59.71 | 408,600 |
| 2026-05-21 | $60.41 | 396,300 |
| 2026-05-20 | $60.08 | 444,600 |
| 2026-05-19 | $59.77 | 414,300 |
| 2026-05-18 | $58.74 | 535,600 |
| 2026-05-15 | $63.15 | 448,400 |
| 2026-05-14 | $62.19 | 469,500 |
| 2026-05-13 | $62.69 | 844,300 |
| 2026-05-12 | $65.58 | 853,900 |
| 2026-05-11 | $67.92 | 504,100 |
| 2026-05-08 | $69.33 | 490,500 |
| 2026-05-07 | $66.96 | 1,414,900 |
| 2026-05-06 | $67.36 | 681,000 |
About AnaptysBio, Inc.
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
đ° Latest News
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
Zacks âĸ 2026-05-21T13:40:03Z
Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?
Zacks âĸ 2026-05-19T13:55:02Z
How The Grupo TraxiÃŗn (BMV:TRAXION A) Story Is Shifting With Cautious New Analyst Targets
Simply Wall St. âĸ 2026-05-15T14:18:45Z
AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Zacks âĸ 2026-05-14T13:55:02Z
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
Zacks âĸ 2026-05-11T15:50:00Z
Assessing AnaptysBio (ANAB) Valuation After Royalty Pivot Spinoff And Legal Outcome
Simply Wall St. âĸ 2026-05-11T01:10:19Z
Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?
Insider Monkey âĸ 2026-05-10T23:13:55Z
Why These Four Biotech Stocks Prove That Follow-On Entries Still Pop Up In Stock Market Leaders
Investor's Business Daily âĸ 2026-05-08T19:45:40Z
TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View
Zacks âĸ 2026-05-07T16:08:00Z
Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised
Zacks âĸ 2026-05-07T16:04:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $234,603,000 | $91,280,000 | $17,157,000 | $10,287,000 |
| Operating Revenue | $234,603,000 | $91,280,000 | $17,157,000 | $10,287,000 |
| Expenses | ||||
| Interest Expense | $79,893,000 | $50,087,000 | $18,083,000 | $21,108,000 |
| Total Expenses | $186,707,000 | $206,229,000 | $174,229,000 | $125,441,000 |
| Other Income Expense | $5,430,000 | $14,000 | $-7,341,000 | $12,000 |
| Other Non Operating Income Expenses | $5,430,000 | $14,000 | $-2,000 | $12,000 |
| Net Non Operating Interest Income Expense | $-66,394,000 | $-30,293,000 | $790,000 | $-13,558,000 |
| Interest Expense Non Operating | $79,893,000 | $50,087,000 | $18,083,000 | $21,108,000 |
| Operating Expense | $186,707,000 | $206,229,000 | $174,229,000 | $125,441,000 |
| General And Administrative Expense | $50,737,000 | $42,389,000 | $41,946,000 | $36,643,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-13,232,000 | $-145,231,000 | $-163,619,000 | $-128,724,000 |
| Net Interest Income | $-66,394,000 | $-30,293,000 | $790,000 | $-13,558,000 |
| Interest Income | $13,499,000 | $19,794,000 | $18,873,000 | $7,550,000 |
| Normalized Income | $-13,232,000 | $-145,231,000 | $-156,280,179 | $-128,724,000 |
| Net Income From Continuing And Discontinued Operation | $-13,232,000 | $-145,231,000 | $-163,619,000 | $-128,724,000 |
| Total Operating Income As Reported | $47,896,000 | $-114,949,000 | $-164,411,000 | $-115,154,000 |
| Net Income Common Stockholders | $-13,232,000 | $-145,231,000 | $-163,619,000 | $-128,724,000 |
| Net Income | $-13,232,000 | $-145,231,000 | $-163,619,000 | $-128,724,000 |
| Net Income Including Noncontrolling Interests | $-13,232,000 | $-145,231,000 | $-163,619,000 | $-128,724,000 |
| Net Income Continuous Operations | $-13,232,000 | $-145,231,000 | $-163,619,000 | $-128,724,000 |
| Pretax Income | $-13,068,000 | $-145,228,000 | $-163,623,000 | $-128,700,000 |
| Special Income Charges | $0 | $0 | $-7,339,000 | $0 |
| Interest Income Non Operating | $13,499,000 | $19,794,000 | $18,873,000 | $7,550,000 |
| Operating Income | $47,896,000 | $-114,949,000 | $-157,072,000 | $-115,154,000 |
| Per Share | ||||
| Diluted EPS | $-0.46 | $-5.12 | $-6.08 | $-4.57 |
| Basic EPS | $-0.46 | $-5.12 | $-6.08 | $-4.57 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $-179 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $69,248,000 | $-92,744,000 | $-135,825,000 | $-105,257,000 |
| Total Unusual Items | $0 | $0 | $-7,339,000 | $0 |
| Total Unusual Items Excluding Goodwill | $0 | $0 | $-7,339,000 | $0 |
| Reconciled Depreciation | $2,423,000 | $2,397,000 | $2,376,000 | $2,335,000 |
| EBITDA (Bullshit earnings) | $69,248,000 | $-92,744,000 | $-143,164,000 | $-105,257,000 |
| EBIT | $66,825,000 | $-95,141,000 | $-145,540,000 | $-107,592,000 |
| Diluted Average Shares | $28,758,000 | $28,382,000 | $26,924,000 | $28,165,000 |
| Basic Average Shares | $28,758,000 | $28,382,000 | $26,924,000 | $28,165,000 |
| Diluted NI Availto Com Stockholders | $-13,232,000 | $-145,231,000 | $-163,619,000 | $-128,724,000 |
| Tax Provision | $164,000 | $3,000 | $-4,000 | $24,000 |
| Restructuring And Mergern Acquisition | $0 | $0 | $7,339,000 | $0 |
| Research And Development | $135,970,000 | $163,840,000 | $132,283,000 | $88,798,000 |
| Selling General And Administration | $50,737,000 | $42,389,000 | $41,946,000 | $36,643,000 |
| Other Gand A | $50,737,000 | $42,389,000 | $41,946,000 | $36,643,000 |
| Other Special Charges | - | - | $7,339,000 | - |
Fetched: 2026-06-06
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $37,210,000 | $70,868,000 | $88,103,000 | $262,103,000 |
| Total Assets | $364,395,000 | $483,834,000 | $452,389,000 | $610,383,000 |
| Total Non Current Assets | $14,145,000 | $51,958,000 | $45,554,000 | $163,178,000 |
| Other Non Current Assets | $256,000 | $256,000 | $256,000 | $256,000 |
| Current Assets | $350,250,000 | $431,876,000 | $406,835,000 | $447,205,000 |
| Other Current Assets | $4,762,000 | $5,738,000 | $9,080,000 | $4,545,000 |
| Receivables | $33,850,000 | $40,765,000 | $6,851,000 | $1,419,000 |
| Accounts Receivable | $33,850,000 | $40,765,000 | $6,851,000 | $1,419,000 |
| Cash Cash Equivalents And Short Term Investments | $311,638,000 | $385,373,000 | $390,904,000 | $441,241,000 |
| Cash And Cash Equivalents | $238,196,000 | $123,080,000 | $35,965,000 | $71,308,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $14,112,000 | $16,037,000 | $17,814,000 | $19,450,000 |
| Long Term Debt And Capital Lease Obligation | $12,032,000 | $14,112,000 | $16,037,000 | $17,813,000 |
| Current Debt And Capital Lease Obligation | $2,080,000 | $1,925,000 | $1,777,000 | $1,637,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $327,185,000 | $412,966,000 | $364,286,000 | $348,280,000 |
| Total Non Current Liabilities Net Minority Interest | $288,560,000 | $367,538,000 | $326,844,000 | $322,226,000 |
| Other Non Current Liabilities | $276,528,000 | $353,426,000 | $310,807,000 | $304,413,000 |
| Current Liabilities | $38,625,000 | $45,428,000 | $37,442,000 | $26,054,000 |
| Payables And Accrued Expenses | $25,451,000 | $35,054,000 | $28,464,000 | $19,038,000 |
| Payables | $3,871,000 | $4,002,000 | $4,698,000 | $2,784,000 |
| Accounts Payable | $3,871,000 | $4,002,000 | $4,698,000 | $2,784,000 |
| Equity | ||||
| Common Stock Equity | $37,210,000 | $70,868,000 | $88,103,000 | $262,103,000 |
| Total Equity Gross Minority Interest | $37,210,000 | $70,868,000 | $88,103,000 | $262,103,000 |
| Stockholders Equity | $37,210,000 | $70,868,000 | $88,103,000 | $262,103,000 |
| Gains Losses Not Affecting Retained Earnings | $-24,000 | $305,000 | $-797,000 | $-5,246,000 |
| Other Equity Adjustments | $-24,000 | $305,000 | $-797,000 | $-5,246,000 |
| Retained Earnings | $-772,559,000 | $-759,327,000 | $-614,096,000 | $-450,477,000 |
| Other | ||||
| Ordinary Shares Number | $28,019,000 | $30,473,000 | $26,597,000 | $28,513,000 |
| Share Issued | $28,019,000 | $30,473,000 | $26,597,000 | $28,513,000 |
| Tangible Book Value | $37,210,000 | $70,868,000 | $88,103,000 | $262,103,000 |
| Invested Capital | $37,210,000 | $70,868,000 | $88,103,000 | $262,103,000 |
| Working Capital | $311,625,000 | $386,448,000 | $369,393,000 | $421,151,000 |
| Capital Lease Obligations | $14,112,000 | $16,037,000 | $17,814,000 | $19,450,000 |
| Total Capitalization | $37,210,000 | $70,868,000 | $88,103,000 | $262,103,000 |
| Additional Paid In Capital | $809,765,000 | $829,860,000 | $702,969,000 | $717,797,000 |
| Capital Stock | $28,000 | $30,000 | $27,000 | $29,000 |
| Common Stock | $28,000 | $30,000 | $27,000 | $29,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $12,032,000 | $14,112,000 | $16,037,000 | $17,813,000 |
| Current Capital Lease Obligation | $2,080,000 | $1,925,000 | $1,777,000 | $1,637,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $11,094,000 | $8,449,000 | $7,201,000 | $5,379,000 |
| Current Accrued Expenses | $21,580,000 | $31,052,000 | $23,766,000 | $16,254,000 |
| Investments And Advances | $0 | $35,470,000 | $27,026,000 | $142,935,000 |
| Net PPE | $13,889,000 | $16,232,000 | $18,272,000 | $19,987,000 |
| Accumulated Depreciation | $-7,139,000 | $-6,599,000 | $-6,218,000 | $-5,576,000 |
| Gross PPE | $21,028,000 | $22,831,000 | $24,490,000 | $25,563,000 |
| Leases | $203,000 | $203,000 | $203,000 | $203,000 |
| Other Properties | $19,242,000 | $21,098,000 | $22,647,000 | $23,767,000 |
| Machinery Furniture Equipment | $1,583,000 | $1,530,000 | $1,640,000 | $1,593,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $73,442,000 | $262,293,000 | $354,939,000 | $369,933,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-06
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $19,610,000 | $-135,695,000 | $-121,607,000 | $-73,951,000 |
| Operating Activities | ||||
| Operating Cash Flow | $19,697,000 | $-135,337,000 | $-120,800,000 | $-73,593,000 |
| Cash Flow From Continuing Operating Activities | $19,697,000 | $-135,337,000 | $-120,800,000 | $-73,593,000 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-87,000 | $-358,000 | $-807,000 | $-358,000 |
| Investing Cash Flow | $228,032,000 | $95,398,000 | $144,754,000 | $-394,845,000 |
| Cash Flow From Continuing Investing Activities | $228,032,000 | $95,398,000 | $144,754,000 | $-394,845,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-68,626,000 | $-456,000 | $-50,000,000 | $0 |
| Issuance Of Capital Stock | $14,261,000 | $100,842,000 | $2,472,000 | $11,827,000 |
| Financing Cash Flow | $-132,613,000 | $127,054,000 | $-59,297,000 | $44,017,000 |
| Cash Flow From Continuing Financing Activities | $-132,613,000 | $127,054,000 | $-59,297,000 | $44,017,000 |
| Net Other Financing Charges | $-76,797,000 | $34,172,000 | $-11,769,000 | $32,190,000 |
| Net Common Stock Issuance | $-54,365,000 | $100,386,000 | $-47,528,000 | $11,827,000 |
| Common Stock Issuance | $14,261,000 | $100,842,000 | $2,472,000 | $11,827,000 |
| Other | ||||
| Interest Paid Supplemental Data | $79,994,000 | $42,132,000 | $0 | $0 |
| Income Tax Paid Supplemental Data | $78,000 | $0 | $0 | - |
| End Cash Position | $238,196,000 | $123,080,000 | $35,965,000 | $71,308,000 |
| Beginning Cash Position | $123,080,000 | $35,965,000 | $71,308,000 | $495,729,000 |
| Changes In Cash | $115,116,000 | $87,115,000 | $-35,343,000 | $-424,421,000 |
| Proceeds From Stock Option Exercised | $-1,451,000 | $-7,504,000 | $0 | $0 |
| Common Stock Payments | $-68,626,000 | $-456,000 | $-50,000,000 | $0 |
| Net Investment Purchase And Sale | $228,119,000 | $95,756,000 | $145,561,000 | $-394,487,000 |
| Sale Of Investment | $424,530,000 | $476,132,000 | $449,480,000 | $408,016,000 |
| Purchase Of Investment | $-196,411,000 | $-380,376,000 | $-303,919,000 | $-802,503,000 |
| Net PPE Purchase And Sale | $-87,000 | $-358,000 | $-807,000 | $-358,000 |
| Purchase Of PPE | $-87,000 | $-358,000 | $-807,000 | $-358,000 |
| Change In Working Capital | $-80,725,000 | $-66,325,000 | $-324,000 | $6,839,000 |
| Change In Other Current Liabilities | $-1,925,000 | $-1,777,000 | $-1,636,000 | $-1,505,000 |
| Change In Payables And Accrued Expense | $-87,327,000 | $-33,837,000 | $10,938,000 | $9,700,000 |
| Change In Payable | $-87,327,000 | $-33,837,000 | $10,938,000 | $9,700,000 |
| Change In Account Payable | $-87,327,000 | $-33,837,000 | $10,938,000 | $9,700,000 |
| Change In Prepaid Assets | $1,612,000 | $3,203,000 | $-4,194,000 | $-813,000 |
| Change In Receivables | $6,915,000 | $-33,914,000 | $-5,432,000 | $-543,000 |
| Changes In Account Receivables | $6,915,000 | $-33,914,000 | $-5,432,000 | $-543,000 |
| Other Non Cash Items | $79,893,000 | $50,087,000 | $18,083,000 | $21,108,000 |
| Stock Based Compensation | $36,072,000 | $34,048,000 | $33,205,000 | $27,356,000 |
| Amortization Of Securities | $-4,734,000 | $-10,313,000 | $-10,521,000 | $-2,507,000 |
| Depreciation Amortization Depletion | $2,423,000 | $2,397,000 | $2,376,000 | $2,335,000 |
| Depreciation And Amortization | $2,423,000 | $2,397,000 | $2,376,000 | $2,335,000 |
| Depreciation | $2,423,000 | $2,397,000 | $2,376,000 | $2,335,000 |
| Net Income From Continuing Operations | $-13,232,000 | $-145,231,000 | $-163,619,000 | $-128,724,000 |
| Sale Of PPE | - | - | $0 | $0 |
| Gain Loss On Sale Of PPE | - | - | $0 | $0 |
| Repayment Of Debt | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
Fetched: 2026-06-06